SPDR S&P Pharmaceuticals ETF Rating $72.80 0.00 (0.00%) As of 08/21/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest SPDR S&P Pharmaceuticals ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XPH Aggregate RatingModerate Buy 2.67Holdings in XPH have an aggregate rating of Moderate Buy based on 322 analyst ratings issued in the past year covering 25 companies (51.5% of the portfolio).XPH Aggregate Price Target$72.80High Prediction$72.80Average Prediction$72.80Low Prediction$72.80Holdings in XPH have an aggregate price target of $72.80 and a range of $72.80 to $72.80 covering 25 companies (51.5% of the portfolio).XPH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy6 Buy rating(s)Moderate Buy14 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 XPH Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings3.62%CRNXCrinetics Pharmaceuticals$84.691.9437 of 5 stars2.24$81.00 -4.4%17Positive News3.19%MBXMBX Biosciences$66.332.6517 of 5 stars2.77$77.00 16.1%13Analyst ForecastGap Up2.82%ATAIAtai Beckley$7.383.4037 of 5 stars2.06$10.56 43.0%16Analyst Revision2.78%DFTXDefinium Therapeutics$44.913.1069 of 5 stars3.00$63.00 40.3%20Gap Up2.50%OMEROmeros$19.273.6112 of 5 stars2.67$38.00 97.2%6Insider TradeGap Down2.46%AMLXAmylyx Pharmaceuticals$38.661.7833 of 5 stars3.00$36.25 -6.2%11Trending NewsGap Up2.31%ELVNEnliven Therapeutics$59.823.0719 of 5 stars2.78$75.00 25.4%92.08%CORTCorcept Therapeutics$122.253.4577 of 5 stars2.50$138.17 13.0%8Trending NewsAnalyst Revision1.99%TRVITrevi Therapeutics$17.963.0311 of 5 stars3.00$27.08 50.8%13Positive NewsOptions VolumeGap Up1.97%NKTRNektar Therapeutics$74.022.9078 of 5 stars2.69$141.50 91.2%13Trending NewsAnalyst Forecast1.96%NUVBNuvation Bio$6.92-0.1%3.7048 of 5 stars2.69$13.00 87.9%13Analyst ForecastInsider Trade1.93%EWTXEdgewise Therapeutics$44.182.7971 of 5 stars2.82$50.33 13.9%11Positive News1.79%ALMSAlumis$24.173.1568 of 5 stars2.75$40.30 66.7%12Analyst UpgradeGap Down1.76%MANEVeradermics$103.33+0.5%2.2102 of 5 stars2.67$153.00 48.1%9Insider TradeGap Up1.71%BMYBristol Myers Squibb$67.06+0.1%4.2181 of 5 stars2.56$66.06 -1.5%25Trending News1.71%LGNDLigand Pharmaceuticals$286.293.7388 of 5 stars3.00$335.75 17.3%91.70%OCULOcular Therapeutix$11.083.3249 of 5 stars2.77$25.75 132.4%13Positive NewsGap Up1.69%PRGOPerrigo$14.22-0.2%3.7244 of 5 stars2.00$19.33 36.0%6Gap Down1.68%MRKMerck & Co., Inc.$152.43-0.1%4.2151 of 5 stars2.65$144.10 -5.5%23Trending NewsAnalyst ForecastGap Down1.66%TARSTarsus Pharmaceuticals$72.703.2599 of 5 stars2.78$90.50 24.5%91.66%MAZEMaze Therapeutics$29.432.1266 of 5 stars3.00$66.00 124.3%11Positive News1.66%AMRXAmneal Pharmaceuticals$17.912.4059 of 5 stars3.00$17.67 -1.4%81.63%LQDALiquidia$68.624.2981 of 5 stars2.45$98.08 42.9%11Insider TradeGap Up1.62%JNJJohnson & Johnson$270.69+0.2%4.5999 of 5 stars2.80$268.22 -0.9%25Trending News1.61%EYPTEyepoint Pharmaceuticals$5.322.3474 of 5 stars2.45$28.11 428.4%11Analyst UpgradeGap Up This page (NYSEARCA:XPH) was last updated on 8/24/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredBank of America grew this stake 139%Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Pharmaceuticals ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XPH Stock Alerts